The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
$250 OBC for two weeks on UK Princess.
Book 3 two week cruises on princess and you have your money back if you bought 100 shares at todays price.
Not going to change the world but if you cruise a lot its alright benefit to have .
Picked up some more last week. If you like cruising with any of the CCL brands last week was a great time to buy some shares. About 5 two week cruises and you would have 100% return on your investment via OBC.
40m for the champions of Scotland if they gain automatic entry in next years CL. Still not guaranteed automatic entry but looking likely. Well done Celtic for nipping that blip year in the bud.
I think the Ukrainians have shown him what time it is. Putin has helped blow away any fears the world may have had about Russians military powers. Legacy nukes is what he has. Other than that they would be flattened.
Vladimir Putin
Abramovich was the first person to recommend to Yeltsin that Vladimir Putin be his successor as the Russian president.[51]:?135? When Putin formed his first cabinet as Prime Minister in 1999, Abramovich interviewed each of the candidates for cabinet positions before they were approved.[34]:?102? Subsequently, Abramovich would remain one of Putin's closest confidants. In 2007, Putin consulted in meetings with Abramovich on the question of who should be his successor as president; Medvedev was personally recommended by Abramovich.[51]:?135,?271?
Chris Hutchins, a biographer of Putin, described the relationship between the Russian president and Abramovich as like that between a father and a favourite son. Abramovich has said that when he addresses Putin he uses the Russian language's formal "??" (like Spanish "usted" or German "Sie"), as opposed to the informal "??" (like Spanish "tú" or German "du"). Abramovich says that the reason is 'he is more senior than me'.[52] Within the Kremlin, Abramovich is referred to as "Mr A".[53]
In September 2012, the England and Wales High Court judge Elizabeth Gloster claimed that Abramovich's influence on Putin was limited: "There was no evidential basis supporting the contention that Mr Abramovich was in a position to manipulate, or otherwise influence, President Putin, or officers in his administration, to exercise their powers in such a way as to enable Mr Abramovich to achieve his own commercial goals."[54]
Gloster oversaw the case between Russian oligarchs Boris Berezovsky and Abramovich. She found Berezovsky to be "an inherently unreliable witness" and sided with Abramovich in 2012. It later emerged that Gloster's stepson had been paid almost £500,000 to represent Abramovich as a barrister early in the case. Her stepson's involvement was alleged to be more than had been disclosed. Berezovsky stated, "Sometimes I have the impression that Putin himself wrote this judgment". Gloster declined to comment.[55][56][57]
U.S. media reports that the U.S. intelligence community believes Abramovich is a "bag carrier", a financial middleman, for Putin.[58]
Abramovich is one of many Russian "oligarchs" named in the Countering America's Adversaries Through Sanctions Act, CAATSA, signed into law by President Donald Trump in 2017.[59] He is one of the Navalny 35.[60]
Wonder how many clever cloggs got caught trying to make a couple quid on this "bargain".
Get caught with these for a dividend. Maybe worth a punt a lot lower than this price. Major gamble.
I think this stock will finally run out of other peoples money. Been in here since 2008. That purchase back then was never in profit. Bought a batch a few years ago which made profit.
But overall this has just drained investors money for far too long with no return. They should move into PR because this yarn has been spun so long they must be experts.
yes. The short term bottle merchants have been bought up on the ultra cheap.
A bit annoying for any investor who dumped at big loss these because of potential delisting. Luckily i held.
Rene is like playing snooker will rope. Anyone in profit here has been very fortunate with their trimming. This stock has been draining shareholder value for at least 13 years i've been invested . Blink and you cash disappears .
Cinema is more about the experience rather than just the movie itself. If it was all about the movie and sitting at home then home video players in the early 1980s would have killed cinema long ago. What happened was cinema was on its knees and then it reinvented itself and people went back. Bottom line is sitting in your house watching an average movie on your own is not as good as the cinema.
England not even in the top 4 of euro nations and done well with the draw to get this far. Couldn't beat Scotland , needed a dodgy penalty against Denmark. Italy at even money is a gift . 3-1 Italy.
Are you on a permo? I found that post hilarious .
Have a wee acid face for old time sake. ??
https://www.hardmanandco.com/research/corporate-research/poised-for-growth/
TRX is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of marketed regenerative medicine products for the biosurgery, orthopaedics and dental markets. In the past two years, the focus has been on its commercial strategy, restructuring to service demand, and commencing a capacity expansion programme in its US facilities. Phase 1 of the expansion programme has been completed, which, together with the potential return of elective surgeries following the pandemic, positions TRX well for growth and profitability.
Strategy: TRX is building an international regenerative medicine business around its proprietary technology platforms, underpinned by compelling clinical outcomes. Work has begun to expand production capabilities, enabling the business to grow its distribution networks, via strategic partnerships, to drive sales momentum.
Capacity expansion: Phase 1 has been completed through the creation of a new freezer facility (3x capacity) and by moving the distribution and supporting staff into the new facility. This has freed up space in the existing facility to add two new clean rooms, which have come on stream on time and on budget.
Positioning: Through its established network of relationships and distributors, there is strong underlying demand for TRX’s products. The 50% increase in manufacturing capacity will be coming on stream around the time that there is expected to be a return in elective surgeries, positioning TRX for 2H’21 growth.
Risks: The main risk is predicting the timing and pace of recovery from the global pandemic, as well as a recovery in the number of elective surgeries. While all the signals are pointing in the right direction, there can be no certainty that this will occur during 2021. Consequently, TRX is maintaining a cautious stance.
Investment summary: TRX has a portfolio of innovative regenerative products with regulatory approval in both the US and EU. Realignment of its commercial strategy to maximise sales through strategic and distribution partnerships has been successful, resulting in increased demand for its products. TRX is scaling up its manufacturing capacity to meet this pending demand, leaving it well positioned to deliver sales growth when surgeries return, which should result in a re-rating.